A business theme focused on expanding in Asia and overseas by conducting a multinational clinical trial to obtain approval for SP-02 darinaparsin in Japan, South Korea, Taiwan and Hong Kong, licensing out the marketing rights in Japan, and licensing exclusive marketing and other rights in 13 Eastern European countries.